![](https://investorshub.advfn.com/uicon/607320.png?cb=1602587228)
Tuesday, November 03, 2020 5:36:49 AM
Go Leo & IPIX!
Instead of a placebo the other arm will receive treatment either Remdesivir, Favipiravir or convalescent plasma. There is not likely to be a combination arm in this relatively small trial.
It will be interesting to see the dosing regimen approved by the FDA.
We know Brilacidin has a long half life with a short time to virolysis.It also is effective in vitro at low doses. Will the FDA opt for 1,2 or 3 infusions or 2 arms with different doses?
My guess is 2 different doses given 2 or 3 infusions 2-3 days apart.
Fortunately they have experienced researchers to work these matters out.
What will the end points be? The in patient study most likely will evaluate treatment in hospitalized patients on low levels of oxygen without signs of imminent pulmonary failure.
If you are really confident the first end point will be lower mortality[ which no antiviral drug has achieved]if not time to recovery second will be reduced percentage to pulmonary failure or shorten tim oxygen was required and the last will be time to virus neutralization in hospitalized patients .
We should have more details of the human clinical trials in 2-3 weeks. The trial will be short.
For comparison review the Remdesvir Adaptive Covid-19 Treatment Trial (ACTT-1)trial:
https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
GLTA Farrell
Brilacidin In a human lung cell line infected by SARS-CoV-2, Brilacidin achieved a high Selectivity Index rating of 426.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM